Sodium cromoglycate in asthma therapy. A retrospective survey

The data obtained in a retrospective survey of the use and effectiveness of sodium cromoglycate (Lomudal; Fisons) therapy in 635 children and young adults support the findings of other long-term studies that this drug is effective and safe in the treatment of children and young adults with clear evidence of allergy contributing towards their asthma. Its administration by Spinhaler can be commenced successfully at 4 years of age or even younger and continued for as long as is required. The drug is worth a therapeutic trial in any patient with asthma requiring regular medication to control symptoms. The absence of demonstrable allergy does not entirely preclude a favourable response. Once a patient's asthma has been stabilized, sodium cromoglycate enables concomitant therapy (especially with beta 2-adrenergic stimulants and corticosteroids) to be reduced.